Leiden, September 14, 2023 – MIMETAS Scientists established a high-throughput human BBB-on-a-chip to study neuroinflammation and transendothelial migration.

Leiden, August 1, 2023 – MIMETAS researchers report the first large-scale phenotypic screen utilizing Organ-on-a-Chip (OoC) technology. This groundbreaking study was published in the Journal of Angiogenesis.

Leiden July 14, 2023 - A placenta on a chip developed at the University of Dundee has the potential to transform research into life-threatening conditions in pregnancy.

Utrecht, 30 June 2023 - The Center for Animal-Free Biomedical Translation (CPBT) is planning to accelerate the transition to animal-free biomedical innovations. This should offer economic and social benefits: improved medicines and fewer animal tests. MIMETAS (Leiden, The Netherlands), the renowned leader in human tissue and disease modeling using organ-on-a-chip technologies, proudly announces its partnership in the CPBT consortium, focusing on ALS, lower back pain, and protein transition & food allergy. This collaboration marks a significant step towards advancing pharmaceutical, chemical, and food component development while minimizing reliance on animal testing.

 

Leiden June 20, 2023 – MIMETAS, a global leader in human disease modeling announces that it has expanded its ongoing partnership with Astellas, a global pharmaceutical company, to include automation and application support.

Leiden, May 10, 2023 – MIMETAS scientists develop and characterize a pancreatic ductal adenocarcinoma (PDAC) model and applied it to study the role of the endothelium and the stroma in immune cell migration.

Leiden, May 5, 2023 – MIMETAS researchers develop an in vitro model of the placental barrier, which could aid in understanding preeclampsia (PE) and other placental pathologies associated with hypoxia/ischemia.

Leiden, March 28, 2023 – MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company.

Leiden, March 22, 2023 – MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus Infections (HBV).

Leiden, March 7, 2023 - MIMETAS announces that it has launched its Adult Stem Cell-derived Colon and Kidney tubular organoids in an assay ready format.

Leiden, February 24, 2023 – MIMETAS scientists shed light on the potential role of gut-on-a-chip models for studying host-microbial interactions in the context of intestinal physiology.

Leiden, February 3, 2023 – MIMETAS scientists established a 3D Pancreatic Ductal Adenocarcinoma (PDAC) model, enabling the study of cancer treatment response in PDAC organoids.

Leiden, January 30, 2023 – MIMETAS scientists develop a vasculature inflammation model using a scalable and automation-compatible platform and present a method to study vascular barrier integrity in real-time.

Leiden, January 9, 2023 – Scientists from MIMETAS and the University of Texas Health Center develop a model system that supports the culture of clinically relevant PDX cells that recapitulate aspects of the prostate cancer (PCa) tumor microenvironment (TME).

Leiden, November 2, 2022 – MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position.

Leiden, October 10, 2022 – Scientists from MIMETAS and Galapagos used a high-throughput 3D microvessel-on-a-chip on the OrganoPlate platform to study angiogenesis in the context of systemic sclerosis. This article has just been published in Scientific Reports.

Leiden, September 30, 2022 – Scientists from MIMETAS develop a multiplexed assay to quantify reactive oxidative species (ROS) and cell viability in organ-on-a-chip models. This article was published in the Journal of Redox Biology.

LEIDEN, September 8, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel as Chair of its Board of Directors.

Leiden, June 16, 2022 – Scientists from MIMETAS introduce a platform for routine grafting of liver and other tissues on an in vitro grown microvascular bed. This article has just been published in Angiogenesis.

Leiden, May 3, 2022 – MIMETAS announces today that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells.

Leiden, April 14, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund.

New Orleans, April 8-13, 2022 – MIMETAS recently attended the AACR Annual Meeting in person. The AACR Annual Meeting covers the latest discoveries across the spectrum of cancer research.

Leiden, February 24, 2022 – Scientists from MIMETAS and Astellas introduce a combined human renal proximal tubule/blood vessel-on-a-chip model in the OrganoPlate® 3-lane 40 to study acute kidney injury caused by renal ischemia/reperfusion injury. This article has just been published in Kidney360.

Leiden, February 22, 2022 – MIMETAS has been awarded by NC3Rs' CRACK IT Challenges competition with Phase 2 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay.

Leiden, February, 2022 – TEDxBoerhaavedistrictStudio guides us through a virtual ‘Walk in the Park’ with inspiring TEDx speakers from the Boerhaavedistrict in Leiden, The Netherlands. This month, Jos Joore (MIMETAS’ CEO) explains why the development of pharmaceuticals is a hugely expensive and uncertain process and offers a possible solution for more efficient drug development.

Leiden, February 14, 2022 – MIMETAS has just attended the annual SLAS International Conference and Exhibition in person, which took place on February 5-9, 2022, in Boston, Massachusetts. This flagship conference connects great minds in life sciences and technology with each other and with the innovation, technology, and automation needed to transform research each year.

Oegstgeest, January 3, 2022 – In 2019, MIMETAS was granted two-year funding and support by the SME instrument for the project 'OrganoPlate Graft'. The project resulted in the development of the first OrganoReady^® Vascular bed: a ready-to-use OrganoPlate^® Graft with pregrown vascular beds.

Leiden, December 29, 2021 – Scientists from MIMETAS published an article on using microfluidic platforms for modelling and studying Pancreatic Ductal Adenocarcinoma and as translational models for drug screening. Their work was published in Frontiers in Cell and Developmental Biology.

Leiden, December 15, 2021 – Scientists from MIMETAS introduce a new neurovascular unit on-a-chip model to study ischemic events in the human brain. This research has just been published in Fluids and Barriers of the CNS.

Leiden, November 23, 2021 – Scientists from MIMETAS and Astellas introduce a new method to study in vitro drug permeability based on 3D Caco-2 tubules cultured in the OrganoPlate^® 3 lane-40. This article has just been published in the Journal of Pharmaceutical Sciences.

Leiden, October 13, 2021 – Our CEOs Paul Vulto and Jos Joore published a correspondence article about the adoption of organ-on-chip platforms by the pharmaceutical industry. This article has been published in Nature Reviews – Drug Discovery.

Leiden, September 15, 2021 – Scientists from MIMETAS introduce a method to culture intestinal epithelium tubules-on-a-chip in the OrganoPlate^® 3 lane 40. This book chapter has just been published in Methods in Molecular Biology – Organ-on-a-chip Methods and Protocols.

Leiden, August 2, 2021 - Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throughput, artificial membrane-free microfluidic platform. The research has just been published in the International Journal of Molecular Sciences.

Leiden, July 6, 2021 - MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).

Leiden, June 29, 2021 - Scientists from MIMETAS and the UMC Utrecht introduce a new organ-on-a-chip lymphatic vessel model together with a novel long-lived lymphatic cell line to study the lymphatic system in health and disease. This research has been published in ACS Biomaterials Science & Engineering.

Leiden & Tokyo, June 7, 2021 - MIMETAS has been awarded the ‘Deshima Business Award” in the category ‘Newly Established’ by the NCCJ, and the Embassy of the Kingdom of the Netherlands.

Leiden, May 27, 2021 - MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques.

Leiden, April 22, 2021 - MIMETAS, the global leader in organ-on-a-chip-based disease modeling, is happy to announce the appointment of Patrice Denèfle as their Scientific Advisor. Patrice brings in longstanding scientific expertise and an extensive network in the pharmaceutical industry. His involvement will support the therapeutic research strategy and spark new collaborations with leading pharmaceutical companies based on MIMETAS’ phenotypic modeling and screening capabilities.

Leiden, April 16, 2021 - Scientists from MIMETAS, Sciospec and Leiden University introduce an instrument that measures TransEpithelial Electrical Resistance (TEER) of perfused epithelial tubes in the microfluidic OrganoPlate® platform. The research is recently published in the Journal Lab on a Chip.

March 31, 2021 – MIMETAS, Roche Innovation Center, Pfizer, GlaxoSmithKline (GSK), Utrecht Institute for Pharmaceutical Sciences, University of Applied Sciences Northwestern Switzerland, and the Swiss Centre for Applied Human Toxicology, developed a high throughput, 3D microfluidic platform (Nephroscreen) to detect drug-induced nephrotoxicity.

February 9, 2021 – MIMETAS has been awarded by NC3Rs' CRACK IT Challenges competition with Phase 1 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay.

December 10, 2020 – To put new developments in 3D tissue biology in the limelight, MIMETAS organizes 3D-cember every 3rd of December. Videos of the 2020 live-streamed edition are now available on-demand.

March 3, 2020 – Innovative in vitro models ready-to-use for safety, ADME, and toxicology studies in drug development and food & nutrition research.

January 23, 2020 – The Hubrecht institute and MIMETAS investigated if venom molecules produced by snake venom gland organoids also function as actual venom using the OrganoPlate^® platform.

October 1, 2019 – MIMETAS and Hubrecht Organoid Technology (HUB) entered into a strategic collaboration to market organoid models on a chip.

March 5, 2019 – Leading stem cell research group and global leader in organ-on-a-chip technology develop stem cell-derived kidney tubules in microfluidic chips.

April 11, 2018 – Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new product development.

March 17, 2018 – MIMETAS in a consortium to develop in vitro placenta models.

January 1, 2018 – MIMETAS is partner of the Interreg project 'Biomat' aiming to develop a platform for high-throughput testing of biomaterials in a physiologically relevant environment on-a-chip.

October 8, 2014 – MIMETAS B.V. announces that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology.